Drug news
Valeant Pharmaceuticals and Progenics announce the US launch of Relistor (methylnaltrexone bromide) Tablets to treat opioid-induced constipation in adults with chronic non-cancer pain .
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc.announced the U.S. commercial launch of Relistor (methylnaltrexone bromide) Tablets, which is now available for prescribing. Relistor Tablets (450 mg once daily) were approved by the FDA for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins